Clin Exp Otorhinolaryngol.  2015 Mar;8(1):57-64. 10.3342/ceo.2015.8.1.57.

Characteristics of Expression of Matrix Metalloproteinases (MMP-2 and MMP-9) in Glottic Squamous Cell Carcinoma and Benign Vocal Fold Lesions

• Uloza V
• Liutkevicius V
• Pangonyte
• Lesauskaite V

• KMID: 1973489
• DOI: http://doi.org/10.3342/ceo.2015.8.1.57

Abstract

OBJECTIVES
The aim of this study was to investigate expression profile of matrix metalloproteinases (MMP-2 and MMP-9) in glottic squamous cell carcinoma (SCC) and benign vocal fold lesions (BVFLs) and to correlate it with clinical and pathological features.
METHODS
The immunohistochemical expression of MMP-2 and MMP-9 was investigated in specimens taken from 217 patients group, including vocal fold polyps (n=39), recurrent respiratory papillomatosis (n=30), laryngeal keratosis (n=36), glottic SCC (n=112), and the normal tissue of vocal fold (n=12, control group). The expression of MMP-2 and MMP-9, both in epithelium and stroma cells, was graded on a semiquantitative scale, ranging from 0 (no expression) to 18 points (high expression).
RESULTS
Expressions of both, MMP-2 and MMP-9 were significantly higher in the glottic SCC group comparing with BVFL group. Significant higher expression of parenchymal MMP-2 (P<0.001) and stromal MMP-9 (P=0.01) was revealed in the group of moderate/poorly differentiated glottic SCC comparing with well differentiated glottic SCC group. Expression of stroma MMP-2 was found to be correlated with nodal metastasis (P=0.030). Expressions of both, MMP-2 and MMP-9 were not correlated with clinical stage, tumor T value, smoking, alcohol use, age in the glottic SSC patients group. The MMP-2 stroma value of 11.2 points was determined as the optimum point (limiting value) for separating BVFL and glottic SCC patient groups.
CONCLUSION
Our results suggest that expressions of both MMP-2 and MMP-9 are up-regulated already in the development of BVFL, the next determinant step is concerned with occurrence of malignization. Limiting value of stroma MMP-2 demonstrates prognostic importance of MMP-2 in glottic SCC carcinogenesis.

Keyword

Matrix Metalloproteinases; Laryngeal Neoplasms; Lymph Nodes; Neoplasm Metastasis

MeSH Terms

Carcinogenesis
Carcinoma, Squamous Cell*
Epithelium
Humans
Keratosis
Laryngeal Neoplasms
Lymph Nodes
Matrix Metalloproteinases*
Neoplasm Metastasis
Papilloma
Polyps
Smoke
Smoking
Vocal Cords*
Matrix Metalloproteinases
Smoke

Figure

• 

  Fig. 1 Immunohistochemical expression of MMP-9, MMP-2 in samples from glottic squamous cell carcinoma (×20). Neoplastic epithelial/parenchyma (white arrow) and stroma cells (black arrow) demonstrate high expression of MMP-9 (A) and high expression of MMP-2 in stroma cells and moderate expression in epithelial/parenchyma cells (B). MMP, matrix metalloproteinase.

• 

  Fig. 2 Graphical comparison of MMP-2 expression (boxes represent medians and 25%-75% of cases) among glottic SCC and benign vocal fold lesions patients' groups. MMP, matrix metalloproteinase; SCC, squamous cell carcinoma; LK, laryngeal keratosis; VFP, vocal fold polyps; RRP, recurrent laryngeal papillomas.

• 

  Fig. 3 Graphical comparison of MMP-9 expression (boxes represent medians and 25%-75% of cases) among glottic SCC and benign focal fold lesions patients' groups. MMP, matrix metalloproteinase; SCC, squamous cell carcinoma; LK, laryngeal keratosis; VFP, vocal fold polyps; RRP, recurrent laryngeal papillomas.

Reference

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007; Jan-Feb. 57(1):43–66. PMID: 17237035.

2. Ward EC, Van As-Brooks C. Head and neck cancer: treatment, rehabilitation, and outcomes. San Diego (CA): Plural Publishing;2007.

3. Rudolph E, Dyckhoff G, Becher H, Dietz A, Ramroth H. Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: a systematic review and a meta-analysis. Eur Arch Otorhinolaryngol. 2011; 2. 268(2):165–179. PMID: 20957488.

4. Zhang H, Liu M, Sun Y, Lu J. MMP-14 can serve as a prognostic marker in patients with supraglottic cancer. Eur Arch Otorhinolaryngol. 2009; 9. 266(9):1427–1434. PMID: 19283401.

5. Tan CT, Chu CY, Lu YC, Chang CC, Lin BR, Wu HH, et al. CXCL12/CXCR4 promotes laryngeal and hypopharyngeal squamous cell carcinoma metastasis through MMP-13-dependent invasion via the ERK1/2/AP-1 pathway. Carcinogenesis. 2008; 8. 29(8):1519–1527. PMID: 18487224.

6. Liu Y, Li Y, Liu Z, Zhang L, Anniko M, Duan M. Prognostic significance of matrix metalloproteinase-20 overexpression in laryngeal squamous cell carcinoma. Acta Otolaryngol. 2011; 7. 131(7):769–773. PMID: 21466263.

7. Lee SY, Park SY, Kim SH, Choi EC. Expression of matrix metalloproteinases and their inhibitors in squamous cell carcinoma of the tonsil and their clinical significance. Clin Exp Otorhinolaryngol. 2011; 6. 4(2):88–94. PMID: 21716956.

8. Vihinen P, Ala-aho R, Kahari VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets. 2005; 5. 5(3):203–220. PMID: 15892620.

9. Sarioglu S, Ozer E, Kirimca F, Sis B, Pabuccuoglu U. Matrix metalloproteinase-2 expression in laryngeal preneoplastic and neoplastic lesions. Pathol Res Pract. 2001; 197(7):483–486. PMID: 11482578.

10. Bogusiewicz M, Stryjecka-Zimmer M, Szymanski M, Rechberger T, Golabek W. Activity of matrix metalloproteinases-2 and -9 in advanced laryngeal cancer. Otolaryngol Head Neck Surg. 2003; 1. 128(1):132–136. PMID: 12574771.

11. Peschos D, Damala C, Stefanou D, Tsanou E, Assimakopoulos D, Vougiouklakis T, et al. Expression of matrix metalloproteinase-9 (gelatinase B) in benign, premalignant and malignant laryngeal lesions. Histol Histopathol. 2006; 6. 21(6):603–608. PMID: 16528670.

12. Christopoulos TA, Papageorgakopoulou N, Ravazoula P, Mastronikolis NS, Papadas TA, Theocharis DA, et al. Expression of metalloproteinases and their tissue inhibitors in squamous cell laryngeal carcinoma. Oncol Rep. 2007; 10. 18(4):855–860. PMID: 17786346.

13. Bartlett RS, Heckman WW, Isenberg J, Thibeault SL, Dailey SH. Genetic characterization of vocal fold lesions: leukoplakia and carcinoma. Laryngoscope. 2012; 2. 122(2):336–342. PMID: 22252855.

14. Liu WW, Zeng ZY, Wu QL, Hou JH, Chen YY. Overexpression of MMP-2 in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Otolaryngol Head Neck Surg. 2005; 3. 132(3):395–400. PMID: 15746850.

15. Karahan N, Baspinar S, Yariktas M, Kapucuoglu N. Matrix Metalloproteinases (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) expressions in vocal fold polyps. J Voice. 2009; 1. 23(1):29–33. PMID: 17624726.

16. Katayama A, Bandoh N, Kishibe K, Takahara M, Ogino T, Nonaka S, et al. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res. 2004; 1. 10(2):634–640. PMID: 14760086.

17. Gorogh T, Beier UH, Baumken J, Meyer JE, Hoffmann M, Gottschlich S, et al. Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas. Head Neck. 2006; 1. 28(1):31–39. PMID: 16265652.

18. Whittaker M, Ayscough A. Matrix metalloproteinases and their inhibitors: current status and future challenges. Celltransmissions. 2001; 2. 17(1):3–14.

19. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000; 3. 18(5):1135–1149. PMID: 10694567.

20. Danilewicz M, Sikorska B, Wagrowska-Danilewicz M. Prognostic significance of the immunoexpression of matrix metalloproteinase MMP2 and its inhibitor TIMP2 in laryngeal cancer. Med Sci Monit. 2003; 3. 9(3):MT42–MT47. PMID: 12640351.

21. Jodele S, Blavier L, Yoon JM, DeClerck YA. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev. 2006; 3. 25(1):35–43. PMID: 16680570.

22. Wittekindt C, Jovanovic N, Guntinas-Lichius O. Expression of matrix metalloproteinase-9 (MMP-9) and blood vessel density in laryngeal squamous cell carcinomas. Acta Otolaryngol. 2011; 1. 131(1):101–106. PMID: 20873997.

23. Hanata K, Yamaguchi N, Yoshikawa K, Mezaki Y, Miura M, Suzuki S, et al. Soluble EMMPRIN (extra-cellular matrix metalloproteinase inducer) stimulates the migration of HEp-2 human laryngeal carcinoma cells, accompanied by increased MMP-2 production in fibroblasts. Arch Histol Cytol. 2007; 12. 70(5):267–277. PMID: 18431027.

24. Xie M, Sun Y, Li Y. Expression of matrix metalloproteinases in supraglottic carcinoma and its clinical implication for estimating lymph node metastases. Laryngoscope. 2004; 12. 114(12):2243–2248. PMID: 15564854.

25. Roepman P, Kemmeren P, Wessels LF, Slootweg PJ, Holstege FC. Multiple robust signatures for detecting lymph node metastasis in head and neck cancer. Cancer Res. 2006; 2. 66(4):2361–2366. PMID: 16489042.

26. Yuce I, Bayram A, Cagli S, Canoz O, Bayram S, Guney E. The role of CD44 and matrix metalloproteinase-9 expression in predicting neck metastasis of supraglottic laryngeal carcinoma. Am J Otolaryngol. 2011; Mar-Apr. 32(2):141–146. PMID: 20434807.

27. Mallis A, Teymoortash A, Mastronikolis NS, Werner JA, Papadas TA. MMP-2 expression in 102 patients with glottic laryngeal cancer. Eur Arch Otorhinolaryngol. 2012; 2. 269(2):639–642. PMID: 21667117.

28. Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clin Cancer Res. 2004; 5. 10(9):3110–3116. PMID: 15131051.

29. Kosunen A, Pirinen R, Ropponen K, Pukkila M, Kellokoski J, Virtaniemi J, et al. CD44 expression and its relationship with MMP-9, clinicopathological factors and survival in oral squamous cell carcinoma. Oral Oncol. 2007; 1. 43(1):51–59. PMID: 16798062.

30. Sun Y, Liu M, Yang B, Li B, Lu J. Role of siRNA silencing of MMP-2 gene on invasion and growth of laryngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2008; 11. 265(11):1385–1391. PMID: 18437407.